Zoetis Inc. (NYSE:ZTS) Shares Sold by Burns J W & Co. Inc. NY

Burns J W & Co. Inc. NY reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 9.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,265 shares of the company’s stock after selling 2,723 shares during the period. Burns J W & Co. Inc. NY’s holdings in Zoetis were worth $4,442,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Darwin Wealth Management LLC purchased a new stake in Zoetis during the third quarter worth approximately $31,000. First Personal Financial Services acquired a new stake in Zoetis during the third quarter worth approximately $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis during the 3rd quarter worth approximately $33,000. Dunhill Financial LLC boosted its holdings in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares in the last quarter. Finally, Quarry LP grew its position in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

ZTS stock traded up $2.99 on Monday, reaching $166.31. The company had a trading volume of 2,089,210 shares, compared to its average volume of 2,457,063. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The company’s fifty day moving average is $171.71 and its 200 day moving average is $180.29. The company has a market cap of $75.03 billion, a P/E ratio of 31.26, a PEG ratio of 2.91 and a beta of 0.89. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.36 EPS. On average, research analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Leerink Partners started coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.